BIOMAT Database Logo BIOMAT Database Logo

Studies on the control of antibody synthesis. XV. Effect of nonspecific immunodepression on antibody affinity. 1979

E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000915 Antibody Affinity A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. Affinity, Antibody,Antibody Avidity,Avidity, Antibody,Affinities, Antibody,Antibody Affinities,Antibody Avidities,Avidities, Antibody
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D000961 Antilymphocyte Serum Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION. ATGAM,Antilymphoblast Globulins,Antilymphocyte Antibodies,Antilymphocyte Globulin,Lymphocytotoxic Antibodies,Anti-Thymocyte Globulin,Antilymphocyte Immunoglobulin,Antithymocyte Globulin,Antithymoglobulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine),Pressimmune,Anti Thymocyte Globulin,Anti-Thymocyte Globulins,Antibodies, Antilymphocyte,Antibodies, Lymphocytotoxic,Antibody, Antilymphocyte,Antibody, Lymphocytotoxic,Antilymphoblast Globulin,Antilymphocyte Antibody,Antilymphocyte Globulins,Antilymphocyte Immunoglobulins,Antilymphocyte Serums,Antithymocyte Globulins,Antithymoglobulins,Globulin, Anti-Thymocyte,Globulin, Antilymphoblast,Globulin, Antilymphocyte,Globulin, Antithymocyte,Globulins, Anti-Thymocyte,Globulins, Antilymphoblast,Globulins, Antilymphocyte,Globulins, Antithymocyte,Immunoglobulin, Antilymphocyte,Immunoglobulins, Antilymphocyte,Lymphocyte Immune Globulin, Anti Thymocyte Globulin,Lymphocytotoxic Antibody,Serum, Antilymphocyte,Serums, Antilymphocyte
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D013154 Spleen An encapsulated lymphatic organ through which venous blood filters.
D015122 Mercaptopurine An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. 6-Mercaptopurine,1,7-Dihydro-6H-purine-6-thione,6-Mercaptopurine Monohydrate,6-Thiohypoxanthine,6-Thiopurine,6H-Purine-6-thione, 1,7-dihydro-,BW 57-323H,Leupurin,Mecaptopurine Anhydrous,Mercaptopurina Wellcome,Puri-Nethol,Purimethol,Purinethol,6 Mercaptopurine,6 Mercaptopurine Monohydrate,6 Thiohypoxanthine,6 Thiopurine,BW 57 323H,BW 57323H

Related Publications

E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. XVI. Effect of immunodepression on antibody affinity.
January 1980, Cellular immunology,
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. IX. Effect of boosting on antibody affinity.
April 1975, Journal of immunology (Baltimore, Md. : 1950),
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. V. Effect of nonspecific modification of the magnitude of the immune response on the affinity of the antibody synthesized.
March 1974, Journal of immunology (Baltimore, Md. : 1950),
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. XII. Genetic influences on antibody affinity.
April 1978, Immunology,
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. Effect of antibody affinity upon its ability to suppress antibody formation.
January 1968, Immunology,
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. II. Effect of antigen dose and of suppression by passive antibody on the affinity of antibody synthesized.
January 1968, The Journal of experimental medicine,
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. XIV. Role of T cells in regulating antibody affinity.
September 1979, Cellular immunology,
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. VIII. Selection for high affinity antibody production in the secondary response.
August 1975, Immunology,
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the control of antibody synthesis. VI. Effect of antigen dose and time after immunization on antibody affinity and heterogeneity in the mouse.
June 1974, Clinical and experimental immunology,
E A Goidl, and A Cusano, and R Redner, and J B Innes, and M E Weksler, and G W Siskind
Studies on the genetic control of antibody affinity: the independent control of antibody levels and affinity in Biozzi mice.
August 1976, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!